Introduction {#jbmr3241-sec-0002}
============

G‐protein subunit alpha‐11 (Gα~11~) is a major downstream signaling partner of the cell‐surface calcium‐sensing receptor (CaSR), which is a family C G‐protein coupled receptor (GPCR) that plays a pivotal role in the parathyroid and renal regulation of extracellular calcium (Ca^2+^ ~e~) concentrations.[1](#jbmr3241-bib-0001){ref-type="ref"} Gα~11~ belongs to the G~q/11~ class of G‐proteins that enhance phospholipase C (PLC) activity, thereby leading to formation of: inositol 1,4,5‐trisphosphate (IP~3~), which induces rapid increases in intracellular Ca^2+^ (Ca^2+^ ~i~) concentrations; and enhances diacylglycerol (DAG) formation, which in turn activates protein kinase C and the mitogen‐activated protein kinase (MAPK) signaling cascade.[2](#jbmr3241-bib-0002){ref-type="ref"}, [3](#jbmr3241-bib-0003){ref-type="ref"} These signal transduction events allow the CaSR to respond to small fluctuations in the prevailing Ca^2+^ ~e~ concentrations (\[Ca^2+^\]~e~) and to induce alterations in parathyroid hormone (PTH) secretion and urinary calcium excretion.[4](#jbmr3241-bib-0004){ref-type="ref"}

The identification of germline heterozygous mutations of Gα~11~, which is encoded by the *GNA11* gene on chromosome 19p13.3, that result in familial hypocalciuric hypercalcemia (FHH) has demonstrated the importance of this G‐protein subunit in Ca^2+^ ~e~ homeostasis.[5](#jbmr3241-bib-0005){ref-type="ref"} FHH is an autosomal dominant disorder characterized by lifelong elevations of serum calcium concentrations in association with normal or mildly raised serum PTH concentrations and low urinary calcium excretion (calcium‐to‐creatinine clearance ratio \<0.01).[4](#jbmr3241-bib-0004){ref-type="ref"} FHH comprises three genetically distinct conditions, designated as FHH types 1 to 3. FHH1 (OMIM \#145980) is caused by loss‐of‐function CaSR mutations.[1](#jbmr3241-bib-0001){ref-type="ref"} FHH2 (OMIM \#145981) is caused by loss‐of‐function Gα~11~ mutations; to date, three FHH2‐associated mutations have been reported, comprising two missense mutations, Thr54Met and Leu135Gln, and an in‐frame isoleucine deletion at codon 200 (Ile200del)[5](#jbmr3241-bib-0005){ref-type="ref"}, [6](#jbmr3241-bib-0006){ref-type="ref"} (Supporting Fig.  1). FHH3 (OMIM \#600740) is caused by loss‐of‐function mutations of the adaptor protein‐2 sigma subunit‐1 (*AP2S1*) gene, encoding AP2σ, which is involved in the clathrin‐mediated endocytosis of GPCRs, such as the CaSR.[1](#jbmr3241-bib-0001){ref-type="ref"}

Positive allosteric modulators of the CaSR, known as calcimimetics, represent a targeted therapy for patients with symptomatic FHH. Indeed, cinacalcet, a licensed calcimimetic drug, has been used to ameliorate symptomatic hypercalcemia in patients with FHH1 and FHH3.[7](#jbmr3241-bib-0007){ref-type="ref"}, [8](#jbmr3241-bib-0008){ref-type="ref"}, [9](#jbmr3241-bib-0009){ref-type="ref"} However, such effects of cinacalcet in FHH2 patients have not been reported, although cinacalcet has been shown in vitro, to rectify signaling abnormalities associated with FHH2‐causing Gα~11~ mutations.[10](#jbmr3241-bib-0010){ref-type="ref"} Here, we report the effectiveness of cinacalcet in ameliorating the signaling defects and hypercalcemia due to a previously unreported FHH2‐associated Gα~11~ mutation, Phe220Ser.

Patients and Methods {#jbmr3241-sec-0003}
====================

Case report {#jbmr3241-sec-0004}
-----------

The proband (individual II.1, Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *A*) was a 33‐year‐old male who presented with headaches, constipation, and pruritus. Biochemical investigations revealed hypercalcemia, hypophosphatemia, raised plasma PTH concentrations, and a low urine calcium‐to‐creatinine ratio (Table [1](#jbmr3241-tbl-0001){ref-type="table-wrap"}). A DXA scan showed normal bone mineral density values at the spine and hip (Table [1](#jbmr3241-tbl-0001){ref-type="table-wrap"}). A skin biopsy, undertaken to investigate the pruritus, demonstrated folliculitis (Table [1](#jbmr3241-tbl-0001){ref-type="table-wrap"}). His father, and three of his four children, also had hypercalcemia, constipation, and/or headaches (Table [1](#jbmr3241-tbl-0001){ref-type="table-wrap"}). Two of his affected children had eczema, and the proband\'s father had sustained an osteoporotic vertebral fracture. The familial hypercalcemia and reduced urinary calcium excretion were consistent with FHH; however, *CASR* or *AP2S1* mutations were not identified. Informed consent was obtained from individuals and where appropriate, parents and guardians of children, using protocols approved by the Research Ethics Committee of the Helsinki University Hospital.

![Identification and structural assessment of a Phe220Ser Gα~11~ mutation in a family with familial hypocalciuric hypercalcemia type 2. (*A*) The family comprised of 5 affected and 3 unaffected members (top). The proband (individual II.1) is indicated by an arrow. A heterozygous T‐to‐C transition at nucleotide c.659, predicted to result in a missense substitution of the WT Phe to a mutant (m) Ser at codon 220 of the Gα~11~ protein, was identified in the proband and confirmed to cosegregate with hypercalcemia by Sanger DNA sequence analysis. (*B*) Multiple protein sequence alignment of residues comprising the β3‐α2 loop, α2‐helix, and α2‐β4 loop that form switch II (red box) of Gα~11~ orthologs (top) and Gα‐subunit paralogs (bottom). Conserved residues are shown in gray, and WT (Phe, F) and mutant (Ser, S) residues are shown in red. (*C*) Structural model showing that Phe220 of Gα~11~ is part of a hydrophobic cluster of amino acids (yellow) within switch II and the α3‐helix, which stabilize the region in a conformation that facilitates effector binding. (*D*) Close‐up view of Phe220 residue, within the switch II region of the GTPase domain of Gα~11~, in complex with phospholipase C‐β3 (brown space‐filling model), with directly interacting residues of the α2 and α3 helices colored blue.](JBMR-33-32-g001){#jbmr3241-fig-0001}

###### 

Clinical and Biochemical Findings in Available Affected Members of the Family With the Phe220Ser Gα~11~ Mutation

                                                                Individuals                                                                                                                                                                                                                                 
  ------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------
  Sex                                                           Male                                                                         Female                                                                        Male                                                                             Female
  Age at diagnosis                                              33 years                                                                     7 weeks                                                                       At birth                                                                         18 months
  Associated clinical features                                  Headaches, pruritus, constipation[^a^](#jbmr3241-note-0001){ref-type="fn"}   Constipation, scoliosis, headaches[^b^](#jbmr3241-note-0002){ref-type="fn"}   Premature birth,[^c^](#jbmr3241-note-0003){ref-type="fn"} eczema, constipation   Constipation, eczema
  Serum biochemistry[^d^](#jbmr3241-note-0004){ref-type="fn"}                                                                                                                                                                                                                                               
  Ionized calcium (mmol/L)                                      1.42                                                                         1.41                                                                          1.46                                                                             1.46
  Phosphate (mmol/L)                                            0.50                                                                         1.98                                                                          1.81                                                                             1.62
  Alkaline phosphatase (U/L)                                    77                                                                           275                                                                           461                                                                              243
  Magnesium (mmol/L)                                            0.78                                                                         1.00                                                                          0.90                                                                             0.93
  Creatinine (μmol/L)                                           76                                                                           26                                                                            78                                                                               26
  PTH (ng/L)                                                    98                                                                           39                                                                            100                                                                              40
  25‐hydroxyvitamin D (nmol/L)                                  49                                                                           50                                                                            102                                                                              122
  Thyrotropin (TSH) (mU/L)                                      2.82                                                                         1.83                                                                          5.5[^e^](#jbmr3241-note-0005){ref-type="fn"}                                     1.53
  Urinary calcium excretion                                     0.09[^f^](#jbmr3241-note-0006){ref-type="fn"}                                0.002                                                                         0.001                                                                            0.003

A skin biopsy demonstrated folliculitis with keratin within the widened hair follicle and inflammatory cells around the hair follicle. Normal bone mineral density *T*‐score ≥ --1.0 at lumbar spine and femoral neck.

Individual III.2 (Fig. [1](#jbmr3241-fig-0001){ref-type="fig"}) developed headaches from age 10 years.

Individual III.3 was born prematurely at gestational age 27+3 weeks.

Normal biochemical ranges: ionized calcium, 1.16 to 1.30 mmol/L (adults) and 1.16 to 1.39 mmol/L (age 1 to 12 months); phosphate, 1.50 to 2.60 mmol/L (neonates), 1.50 to 2.50 mmol/L (age 1 to 6 months), 1.20 to 1.80 mmol/L (age 2 to 12 years), and 0.71 to 1.53 mmol/L (adults); alkaline phosphatase activity, 35 to 105 U/L (adults) and 115 to 460 U/L (age 15 days to 1 year); magnesium, 0.71 to 0.94 mmol/L (adults) and 0.7 to 1.0 mmol/L (age 3 months to 17 years); creatinine, 60 to 100 μmol/L (adult males) and 10 to 56 μmol/L (age 8 days to 2 years); PTH, 8 to 73 ng/L; 25 hydroxyvitamin D, \>50 nmol/L; thyrotropin; 0.5 to 3.6 mU/L (age \>14 weeks) and 0.4 to 7 mU/L (age 11 to 14 weeks); calcium‐to‐creatinine clearance ratio \>0.02.

TSH concentration measured in umbilical cord blood (normal range not available for premature infant cord blood TSH).

Calcium‐to creatinine ratio, normal 0.3‐0.7.
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Mutational analysis {#jbmr3241-sec-0005}
-------------------

DNA sequence analyses of *GNA11* exons 1 to 7 and adjacent splice sites (NM_002067) was performed using leukocyte DNA and gene‐specific primers (Sigma‐Aldrich, Gillingham, UK), as reported.[5](#jbmr3241-bib-0005){ref-type="ref"}, [6](#jbmr3241-bib-0006){ref-type="ref"} Polymorphic variants were identified from public databases (Supporting Table  1).

Protein sequence alignment and three‐dimensional modeling of Gα~11~ structure {#jbmr3241-sec-0006}
-----------------------------------------------------------------------------

Protein sequences of Gα~11~ orthologs were aligned using ClustalOmega (European Bioinformatics Institute \[EMBL‐EBI\], Cambridgeshire, UK; <http://www.ebi.ac.uk/Tools/msa/clustalo/>).[6](#jbmr3241-bib-0006){ref-type="ref"} Gα~11~ three‐dimensional modeling was undertaken using the reported three‐dimensional structures of: Gα~q~ in complex with phospholipase C‐β3 (Protein Data Bank accession no. 3OHM)[11](#jbmr3241-bib-0011){ref-type="ref"}; Gα~q~ in complex with the small molecule inhibitor YM‐254890 (Protein Data Bank accession no. 3AH8)[12](#jbmr3241-bib-0012){ref-type="ref"}; and Gα~q~ in complex with the regulator of G‐protein signaling 2 (RGS2) (Protein Data Bank accession no. 4EKC and 4QJ3).[13](#jbmr3241-bib-0013){ref-type="ref"}, [14](#jbmr3241-bib-0014){ref-type="ref"} The Gα~q~ protein, which shares 90% identity at the amino acid level with Gα~11~, was used because crystal structures of Gα~11~ are not available. Figures were prepared using the PyMOL Molecular Graphics System, Schrodinger.

Cell culture and transfection {#jbmr3241-sec-0007}
-----------------------------

Mutations were introduced into the previously described pBI‐CMV2‐*GNA11* expression construct by site‐directed mutagenesis using the Quikchange Lightning Kit (Agilent Technologies, Santa Clara, CA, USA) and gene‐specific primers (Sigma‐Aldrich). Wild‐type (WT) or mutant pBI‐CMV2‐*GNA11* constructs were transiently transfected into HEK293 cells stably expressing CaSR (HEK‐CaSR) using Lipofectamine 2000 (Life TechnologiesCarlsbad, CA, USA), as described.[15](#jbmr3241-bib-0015){ref-type="ref"}, [16](#jbmr3241-bib-0016){ref-type="ref"} The pBI‐CMV2‐*GNA11* bidirectional vector allows for co‐expression of Gα~11~ and GFP at equivalent levels.[5](#jbmr3241-bib-0005){ref-type="ref"} HEK‐CaSR cells were maintained in DMEM‐Glutamax media (Gibco, Carlsbad, CA, USA) that has a calcium concentration of 1.80mM. The presence of mutations was verified using dideoxynucleotide sequencing with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies) and an automated detection system (ABI3730 Automated capillary sequencer; Applied Biosystems, Carlsbad, CA, USA).[17](#jbmr3241-bib-0017){ref-type="ref"} Luciferase reporter constructs (pGL4.30‐NFAT, pGL4.33‐SRE) were purchased from Promega. HEK293 cells were used because suitable parathyroid and renal tubular cells are not available, and HEK293 cells have been established as a model for the functional expression of Gα~11~ proteins.[5](#jbmr3241-bib-0005){ref-type="ref"}, [15](#jbmr3241-bib-0015){ref-type="ref"}, [16](#jbmr3241-bib-0016){ref-type="ref"} HEK‐CaSR cells were cultured in high‐glucose DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 1% Geneticin at 37°C, 5% CO~2~.[5](#jbmr3241-bib-0005){ref-type="ref"} Successful transfection was confirmed by visualizing GFP fluorescence using an Eclipse E400 fluorescence microscope with an epifluorescence filter, and images were captured using a DXM1200C digital camera and NIS Elements software (Nikon, Kingston‐Upon‐Thames, UK).[5](#jbmr3241-bib-0005){ref-type="ref"}, [16](#jbmr3241-bib-0016){ref-type="ref"} The expression of Gα~11~ and CaSR proteins was confirmed by Western blot analyses using Gα~11~ (Santa Cruz Biotechnologies), anti‐calnexin (Millipore, Billerica, MA), or anti‐CaSR (Abcam, Cambridge, UK) antibodies. Calnexin, a housekeeping protein, was used as a loading control. The Western blots were visualized using an Immuno‐Star Western C kit (BioRad, Hercules, CA, USA) on a BioRad Chemidoc XRS+ system.[6](#jbmr3241-bib-0006){ref-type="ref"}

Fluo‐4 intracellular calcium assay {#jbmr3241-sec-0008}
----------------------------------

Ca^2+^ ~e~‐induced Ca^2+^ ~i~ responses were measured by Fluo‐4 calcium assays adapted from published methods.[18](#jbmr3241-bib-0018){ref-type="ref"} HEK‐CaSR cells were plated in poly‐L‐lysine treated black‐walled 96‐well plates (Corning, Corning, NY, USA), and transiently transfected with 1000 ng/mL pBI‐CMV2‐*GNA11*. Cells were conditioned in serum‐free media (1.8mM Ca^2+^ ~e~) overnight, then incubated in Ca^2+^‐free and Mg^2+^‐free Hanks Balanced Salt Solution (HBSS) for 1 hour, followed by loading with Fluo‐4 dye, prepared according to manufacturer\'s instructions (Invitrogen). Cells were loaded for 40 min at 37°C, then either a 20% aqueous solution of 2‐hydoxypropyl‐β‐cyclodextrin (vehicle), or 30nM or 100nM cinacalcet was added. Cells were then incubated for a further 20 min at 37°C.[18](#jbmr3241-bib-0018){ref-type="ref"} Baseline measurements were made and CaCl~2~ was injected into each well to increase the \[Ca^2+^\]~e~ in a stepwise manner from 0.5 to 10mM \[Ca^2+^\]~e~, using an automated system. Changes in Ca^2+^ ~i~ were recorded on a PHERAstar instrument (BMG Labtech, Aylesbury, UK) at 37°C with an excitation filter of 485 nm and an emission filter of 520 nm. The peak mean fluorescence ratio of the transient response after each individual stimulus was measured using MARS data analysis software (BMG Labtech), and expressed as a normalized response. Nonlinear regression of concentration‐response curves was performed with GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA) using the normalized response at each \[Ca^2+^\]~e~ for each separate experiment for the determination of the EC~50~ (ie, \[Ca^2+^\]~e~ required for 50% of the maximal response). Assays were performed in four to 12 biological replicates for each of the expression constructs. Statistical analysis was performed using the *F*‐test.[5](#jbmr3241-bib-0005){ref-type="ref"}, [6](#jbmr3241-bib-0006){ref-type="ref"}

Luciferase reporter assay {#jbmr3241-sec-0009}
-------------------------

HEK‐CaSR cells were seeded in 48‐well plates and transiently transfected with 100 ng/mL pBI‐CMV2‐*GNA11* WT or mutant proteins, 100 ng/mL luciferase construct (either pGL4‐NFAT or pGL4‐SRE) and 10 ng/mL pRL control vector for 48 hours. Cells were incubated in serum‐free media for 12 hours, followed by treatment of cells for 4 hours with 0.1mM to 10mM CaCl~2~. Cells were lysed and assays performed with Dual‐Glo luciferase (Promega, Madison, WI, USA) on a Veritas Luminometer (Promega), as described.[19](#jbmr3241-bib-0019){ref-type="ref"} Luciferase:renilla ratios were expressed as fold‐changes relative to responses at basal CaCl~2~ concentrations. For studies with cinacalcet (Cambridge Bioscience, Cambridge, UK), the drug was added to cells, as described.[10](#jbmr3241-bib-0010){ref-type="ref"}, [19](#jbmr3241-bib-0019){ref-type="ref"} All assays were performed using four biological replicates on up to three independent occasions. Statistical analysis was performed by two‐way ANOVA with Tukey\'s multiple‐comparisons test using GraphPad Prism 6.

Measurement of ERK phosphorylation {#jbmr3241-sec-0010}
----------------------------------

HEK‐CaSR cells were seeded in 48‐well plates and transfected with 200 ng/mL WT or mutant Gα~11~, 48 hours prior to performance of assays. Transfected cells were incubated in serum‐free media 12 hours prior to treatment of cells with 0.1mM to 10mM CaCl~2~. Cells were then lysed in Surefire lysis buffer, and AlphaScreen Surefire ERK assays (PerkinElmer, Beaconsfield, UK) measuring phosphorylated and total proteins were performed, as described.[10](#jbmr3241-bib-0010){ref-type="ref"}, [19](#jbmr3241-bib-0019){ref-type="ref"} The fluorescence signal in both assays was measured using the PHERAstar FS microplate reader (BMG Labtech).[19](#jbmr3241-bib-0019){ref-type="ref"} The ratio of phosphorylated ERK (pERK) to total ERK measured at each \[Ca^2+^\]~e~ were normalized to the mean responses of WT‐expressing cells and expressed as a fold‐change of responses obtained at basal (0.1mM) \[Ca^2+^\]~e~. All assay conditions were performed in four biological replicates on up to four independent occasions. Statistical analysis was performed by two‐way ANOVA with Tukey\'s multiple‐comparisons test using GraphPad Prism 6.

Web resources {#jbmr3241-sec-0011}
-------------

Predicted effect of the mutation was assessed using Polyphen‐2 (<http://genetics.bwh.harvard.edu/pph2/>)[20](#jbmr3241-bib-0020){ref-type="ref"} and MutationTasting (<http://www.mutationtaster.org/>).[21](#jbmr3241-bib-0021){ref-type="ref"}

Statistics {#jbmr3241-sec-0012}
----------

All studies involved between four and 16 separate transfection experiments. Statistical analyses for Ca^2+^ ~i~ EC~50~ used the *F‐*test,[19](#jbmr3241-bib-0019){ref-type="ref"} and two‐way ANOVA with Tukey\'s multiple‐comparisons test was used for pERK and luciferase reporter assays. Analyses were undertaken using GraphPad Prism, and a value of *p* \< 0.05 was considered significant.

Results {#jbmr3241-sec-0013}
=======

Identification of a novel Phe220Ser Gα~11~ mutation in a family with FHH2 {#jbmr3241-sec-0014}
-------------------------------------------------------------------------

DNA sequence analysis of *GNA11* in the proband identified a heterozygous T‐to‐C transition at nucleotide c.659 (Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *A*), resulting in a missense substitution of the WT Phe to a mutant Ser at residue 220 of the Gα~11~ protein. Bioinformatic analyses predicted the Phe220Ser variant to be damaging and likely disease‐causing (Polyphen‐2 score = 1, MutationTasting score = 0.99). The absence of this DNA sequence abnormality in \>67,200 exomes from the NHLBI‐ESP and Exome Aggregation Consortium cohorts, together with evolutionary conservation of the Phe220 residue in Gα~11~ orthologs and Gα‐subunit paralogs (Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *B*), also indicated that the Phe220Ser abnormality likely represents a pathogenic mutation rather than a benign polymorphic variant.

The Phe220Ser mutation is located in the switch II region of Gα~11~ and predicted to impair PLC activation {#jbmr3241-sec-0015}
----------------------------------------------------------------------------------------------------------

Homology modeling, using crystal structures of the related Gα~q~ protein,[11](#jbmr3241-bib-0011){ref-type="ref"}, [12](#jbmr3241-bib-0012){ref-type="ref"}, [22](#jbmr3241-bib-0022){ref-type="ref"} revealed the WT Phe220 residue to be located within the α2‐helix of the flexible switch II region of the Gα~11~ GTPase domain (Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *B*, *C*; Supporting Fig. [1](#jbmr3241-fig-0001){ref-type="fig"}), and to comprise part of a hydrophobic cluster of amino acids located within a cleft region formed by switch II and the adjacent α3‐helix that interact with PLC upon G‐protein activation (Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *C*, *D*).[11](#jbmr3241-bib-0011){ref-type="ref"} Substitution of the nonpolar hydrophobic WT Phe220 residue, with the mutant polar hydrophilic Ser220 residue is predicted to disrupt Gα~11~ function by impairing PLC activation and signaling.

The Gα~11~ Phe220Ser mutation impairs Ca^2+^ ~i~ responses {#jbmr3241-sec-0016}
----------------------------------------------------------

The Phe220Ser mutation is predicted to diminish PLC activation, and we therefore assessed its effects on Ca^2+^ ~i~ mobilization, which has previously been shown to be enhanced downstream of PLC by the G~q/11~ proteins.[23](#jbmr3241-bib-0023){ref-type="ref"}, [24](#jbmr3241-bib-0024){ref-type="ref"}, [25](#jbmr3241-bib-0025){ref-type="ref"}, [26](#jbmr3241-bib-0026){ref-type="ref"} HEK‐CaSR cells were transiently transfected with pBI‐CMV2‐*GNA11* constructs expressing the WT (Phe220) or mutant (Ser220) Gα~11~ proteins (Supporting Fig.  2). The Ca^2+^ ~i~ responses of the mutant Ser220 Gα~11~‐expressing HEK‐CaSR cells, revealed that a significantly greater \[Ca^2+^\]~e~ was required to achieve half‐maximal (EC~50~) Ca^2+^ ~i~ responses, when compared with WT‐expressing cells (Fig. [2](#jbmr3241-fig-0002){ref-type="fig"} *A*). Thus, the Ser220 mutant‐expressing cells showed a rightward shift in the concentration‐response curve, with a significantly elevated mean EC~50~ value (*p* \< 0.001) of 2.93mM (95% confidence interval \[CI\], 2.80 to 3.07mM), compared with 2.40mM (95% CI, 2.27 to 2.53mM) for WT‐expressing cells. The Ca^2+^ ~i~ responses were also assessed by measurement of nuclear factor of activated T‐cells (NFAT), which is a downstream mediator of Ca^2+^ ~i~ signaling.[27](#jbmr3241-bib-0027){ref-type="ref"} NFAT fold‐change responses were determined using a luciferase reporter assay, and these studies showed that HEK‐CaSR cells expressing the Ser220 Gα~11~ mutant had a significantly reduced fold‐change response (fold‐change = 2.3 ± 0.3) following exposure to 5mM \[Ca^2+^\]~e~, when compared with WT cells (fold‐change = 4.8 ± 0.4, *p* \< 0.001) (Fig. [2](#jbmr3241-fig-0002){ref-type="fig"} *B*). These data demonstrated that the Gα~11~ Phe220Ser mutation impairs CaSR‐mediated Ca^2+^ ~i~ responses, consistent with a loss‐of‐function associated with FHH2.

![Effect of the mutant Ser220 Gα~11~ on Ca^2+^ ~i~ and ERK signaling in HEK‐CaSR cells. (*A*) Ca^2+^ ~i~ responses to changes in \[Ca^2+^\]~e~ of HEK‐CaSR cells expressing WT (Phe220) or mutant (Ser220) Gα~11~ proteins shown as the mean ± SE of 4 to 11 transfections. The Ser220 Gα~11~ mutant caused a rightward shift in the Ca^2+^ ~i~ concentration‐response curve with significantly increased EC~50~ value compared to WT cells (\*\*\**p* \< 0.0001, *F*‐test). (*B*) \[Ca^2+^\]~e~‐induced NFAT reporter responses, which are activated by elevations of Ca^2+^ ~i~, were assessed in HEK‐CaSR cells expressing WT or mutant Gα~11~ proteins. Responses at each \[Ca^2+^\]~e~ are expressed as a fold‐change of basal \[Ca^2+^\]~e~ responses, and shown as mean ± SE of 12 transfections. NFAT luciferase reporter activity increased in all cells in a concentration‐dependent manner, and was significantly reduced in Ser220 cells compared to WT cells. (*C*) Ca^2+^ ~e~‐induced pERK responses of cells expressing WT or mutant Gα~11~ protein, expressed as a ratio to total ERK levels, and shown as mean ± SE of 8 transfections. (*D*) Ca^2+^ ~e~‐induced SRE reporter responses of cells expressing WT or mutant Gα~11~ protein, expressed compared to basal SRE reporter activity, and shown as mean ± SE of 8 transfections. The Ser220 Gα~11~ mutant was associated with significantly decreased pERK and SRE reporter responses compared to WT. \*\**p* \< 0.01 and \*\*\*\**p* \< 0.0001, by a 2‐way ANOVA with Tukey\'s multiple‐comparisons test.](JBMR-33-32-g002){#jbmr3241-fig-0002}

The Gα~11~ Phe220Ser mutation impairs ERK phosphorylation {#jbmr3241-sec-0017}
---------------------------------------------------------

The ERK protein represents a major component of the MAPK signaling cascade, which has previously been shown to be activated by PLC.[3](#jbmr3241-bib-0003){ref-type="ref"}, [28](#jbmr3241-bib-0028){ref-type="ref"} We assessed the effect of the Gα~11~ Phe220Ser mutation on ERK phosphorylation by measuring changes in pERK in response to increases in Ca^2+^ ~e~ in WT and mutant Ser220 Gα~11~‐expressing cells using the AlphaScreen assay, and also by assessing serum‐response element (SRE)‐mediated transcriptional activity, which is regulated by ERK signaling.[19](#jbmr3241-bib-0019){ref-type="ref"} The pERK responses of the Ser220 Gα~11~ mutant were shown to be significantly reduced. Thus, the Ser220 Gα~11~ mutant led to significant reductions in: pERK‐to‐total ERK ratios (Ser220 response at 5mM Ca^2+^ ~e~ = 3.7 ± 0.4 versus Phe220 = 6.1 ± 0.3, *p* \< 0.0001) (Fig. [2](#jbmr3241-fig-0002){ref-type="fig"} *C*); and to SRE reporter fold‐changes (Ser220 fold‐change at 5mM Ca^2+^ ~e~ = 6.5 ± 0.5 versus Phe220 fold‐change = 11.8 ± 0.7, *p* \< 0.0001) (Fig. [2](#jbmr3241-fig-0002){ref-type="fig"} *D*). Thus, the Gα~11~ Phe220Ser mutation impaired CaSR‐mediated ERK phosphorylation.

Phe220 forms part of a hydrophobic cluster of Gα~11~ residues required for PLC‐mediated signaling {#jbmr3241-sec-0018}
-------------------------------------------------------------------------------------------------

To further determine the mechanistic role of the Phe220 residue and the importance of residue 220 hydrophobicity for Gα~11~ function and PLC‐mediated signaling (Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *C*), we engineered mutations of Phe220 to Leu and Ala, which are hydrophobic residues, and to Arg and Glu, which are hydrophilic positively‐charged and negatively‐charged residues, respectively, and studied their effect on Ca^2+^ ~i~ and ERK responses following transient expression in HEK‐CaSR cells (Fig. [3](#jbmr3241-fig-0003){ref-type="fig"}). The Leu220 and Ala220 Gα~11~ mutants did not alter Ca^2+^ ~i~ responses (Fig. [3](#jbmr3241-fig-0003){ref-type="fig"} *A*, *B*; Supporting Fig. [3](#jbmr3241-fig-0003){ref-type="fig"}), or ERK activity, as measured using the pERK AlphaScreen and SRE reporter assays (Fig. [3](#jbmr3241-fig-0003){ref-type="fig"} *C*, *D*). In contrast, the positively‐charged Arg220, and negatively‐charged Glu220 Gα~11~ mutants, respectively, enhanced and impaired Ca^2+^ ~i~ and ERK signaling responses in HEK‐CaSR cells (Fig. [3](#jbmr3241-fig-0003){ref-type="fig"}, Supporting Fig.  3). Thus, these findings demonstrated that a hydrophobic residue at position 220 is required for signaling via PLC. The enhancement of CaSR‐mediated signaling by the Arg220 Gα~11~ mutant may be explained by its structural effect on the G~11~ heterotrimer. Homology modeling, using crystal structures of the related G~q~ protein in complex with Gβγ,[12](#jbmr3241-bib-0012){ref-type="ref"} revealed that the Arg220 residue faces away from the hydrophobic cluster, into the region at which Gα and Gβγ bind, a hydrophobic region that is necessary for Gα activation[29](#jbmr3241-bib-0029){ref-type="ref"} (Supporting Fig.  4). Disruption of this hydrophobic region has been shown to cause constitutive activation,[29](#jbmr3241-bib-0029){ref-type="ref"} and modeling predicts that the Arg220 residue, which is charged and hydrophilic, disrupts this region, thus enhancing activation by impairing Gαβγ association (Supporting Fig.  4). To investigate the importance of the Gα~11~ hydrophobic cleft, formed by switch II and the α3‐helix (Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *C*, *D*), for PLC activation, we engineered mutations of three other hydrophobic residues, Ile217, Val223, and Trp263, within this region, to either an Ala residue, to retain hydrophobicity, or to a Glu residue, to lose hydrophobicity, and studied the effects of these mutants on Ca^2+^ ~i~ and ERK responses following their transient expression in HEK‐CaSR cells (Supporting Fig.  5). This demonstrated that substitution to Ala of only one hydrophobic residue, Ile217, altered PLC‐mediated signaling (Fig. [4](#jbmr3241-fig-0004){ref-type="fig"} *A*--*C*; Supporting Fig.  6). In contrast, substitution of any of the Ile217, Val223, and Trp263 hydrophobic residues to a Glu residue led to a significant reduction in Ca^2+^ ~i~ and ERK responses (Fig. [4](#jbmr3241-fig-0004){ref-type="fig"} *D*--*F*, Supporting Fig.  6). Thus, hydrophobicity of the switch II‐α3 cleft is important for PLC activation.

![Effect of Gα~11~ residue 220 hydrophobicity on PLC‐mediated signaling. (*A*) Histograms showing Ca^2+^ ~e~‐induced Ca^2+^ ~i~ EC~50~ values with 95% confidence intervals (CIs) for cells expressing WT Phe220 or residue 220 mutant (m) Gα~11~ proteins from 6 to 12 transfections. Statistical analyses were performed using the *F‐*test. The Arg220 Gα~11~ mutant reduced the EC~50~ value, whereas the Glu220 and Ser220 Gα~11~ mutants elevated the EC~50~ value. (*B*) Ca^2+^ ~e~‐induced NFAT reporter responses, which assess Ca^2+^ ~i~ signaling, of cells expressing WT or residue 220 mutant Gα~11~ proteins. Responses at each \[Ca^2+^\]~e~ are expressed as a fold‐change of basal \[Ca^2+^\]~e~ responses, and shown as mean ± SE of 4 to 12 transfections. NFAT luciferase reporter activity increased in all cells in a concentration‐dependent manner, however responses were significantly elevated in Arg220 Gα~11~ mutant, and reduced in Glu220 Gα~11~ mutant cells, compared to WT cells. (*C*) Ca^2+^ ~e~‐induced pERK responses of cells expressing WT or mutant residue 220 Gα~11~ proteins, expressed as a ratio to total ERK levels. The Arg220 mutant was associated with significantly increased responses, and the Glu220 and Ser220 mutants were associated with decreased responses, when compared to WT. Data are shown as mean ± SE of 4 to 8 independent transfections. (*D*) Ca^2+^ ~e~‐induced SRE reporter responses of cells expressing WT or mutant (m) residue 220 Gα~11~ proteins, expressed compared to basal SRE reporter activity. The engineered Arg220 mutant was associated with significantly increased, and the engineered Glu220 and FHH2‐associated Ser220 mutants resulted in decreased responses, when compared to WT. Data are shown as mean ± SE of 4 to 8 independent transfections. Statistical analyses performed using 2‐way ANOVA with Tukey\'s multiple‐comparisons test comparing WT with Gα~11~ mutants Ala220, Arg220, Glu220, and Ser220. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](JBMR-33-32-g003){#jbmr3241-fig-0003}

![Effect of mutating residues within the Gα~11~ switch II‐α3 hydrophobic cluster on PLC‐mediated signaling. (*A*) Histograms showing Ca^2+^ ~e~‐induced Ca^2+^ ~i~ EC~50~ values with 95% CI for cells expressing WT and alanine (Ala) Gα~11~ mutants (m) of residues 217, 223, and 263 Gα~11~ proteins from 4 to 8 independent transfections. Only the Ala217 Gα~11~ mutant increased the EC~50~ value, when compared to WT cells. Statistical analyses were performed using the *F‐*test. (*B*, *C*) Ca^2+^ ~e~‐induced (*B*) NFAT and (*C*) SRE luciferase reporter responses of cells expressing WT or alanine (Ala) Gα~11~ mutants. Responses at each \[Ca^2+^\]~e~ are expressed as a fold‐change of basal \[Ca^2+^\]~e~ responses, and shown as mean ± SE of 4 to 8 transfections. NFAT and SRE reporter responses were significantly reduced in Ala217‐expressing cells compared to WT cells. (*D*) Histograms showing Ca^2+^ ~e~‐induced Ca^2+^ ~i~ EC~50~ values with 95% CI for cells expressing WT and glutamic acid (Glu) Gα~11~ mutants (m) of residues 217, 223, and 263 from 4 to 8 independent transfections. All Glu Gα~11~ mutants increased the EC~50~ value, when compared to WT cells. Statistical analyses were performed using the *F‐*test. (*E*, *F*) Ca^2+^ ~e~‐induced (*E*) NFAT and (*F*) SRE luciferase reporter responses of cells expressing WT or glutamic acid (Glu) Gα~11~ mutants. Responses at each \[Ca^2+^\]~e~ are expressed as a fold‐change of basal \[Ca^2+^\]~e~ responses, and shown as mean ± SE of 4 to 8 transfections. NFAT and SRE reporter responses were significantly reduced in cells expressing all 3 glutamic acid mutants compared to WT cells. Statistical analyses for *B*, *C*, *E*, and *F* were performed using 2‐way ANOVA with Tukey\'s multiple‐comparisons test comparing WT to mutant 217 (green), 223 (red), and 263 (gray) Gα~11~ proteins. \**p* \< 0.05, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](JBMR-33-32-g004){#jbmr3241-fig-0004}

Cinacalcet rectifies the impaired PLC signaling responses and hypercalcemia caused by the Phe220Ser Gα~11~ mutation {#jbmr3241-sec-0019}
-------------------------------------------------------------------------------------------------------------------

To determine whether cinacalcet may be an effective therapy for FHH2, we evaluated the effects of different cinacalcet concentrations (0, 30, and 100nM) on the altered PLC signaling responses due to the Phe220Ser Gα~11~ mutant. Treatment of mutant Ser220 Gα~11~‐expressing HEK‐CaSR cells with 30nM cinacalcet, failed to normalize the impaired Ca^2+^ ~i~ and SRE reporter responses (Fig. [5](#jbmr3241-fig-0005){ref-type="fig"} *A*--*C*); however, 100nM cinacalcet, reduced the EC~50~ values, and increased NFAT and SRE reporter activity (Fig. [5](#jbmr3241-fig-0005){ref-type="fig"} *A*--*C*), such that these values were not significantly different from untreated WT cells. These in vitro findings suggested that higher doses of cinacalcet may be required for the treatment of patients harboring the Phe220Ser Gα~11~ mutation. Cinacalcet was administered to the FHH2 proband as he had symptoms such as headaches, constipation, and pruritus (Table [1](#jbmr3241-tbl-0001){ref-type="table-wrap"}), which may have been caused by the hypercalcemia. The proband was initially commenced on 30 mg/day of oral cinacalcet for 3 months, and in keeping with the above cellular studies, which showed a lack of efficacy when using low cinacalcet concentrations, the 30 mg/day dose failed to normalize his elevated serum calcium concentrations (Fig. [5](#jbmr3241-fig-0005){ref-type="fig"} *D*). However, increasing the dose of cinacalcet to 60 mg/day, successfully lowered the serum concentrations of: ionized calcium from 1.42 to 1.26 mmol/L (normal range, 1.16 to 1.30 mmol/L) (Fig. [5](#jbmr3241-fig-0005){ref-type="fig"} *D*); and PTH from 98 to 58 ng/L (normal range, 8 to 73 ng/L). Although the proband became normocalcemic on cinacalcet, the pruritus, from which he suffered the most, did not resolve, and cinacalcet 60 mg/day was discontinued after 4 months. His hypercalcemia returned upon cessation of cinacalcet therapy (Fig. [5](#jbmr3241-fig-0005){ref-type="fig"} *D*).

![Effect of cinacalcet on the loss‐of‐function and hypercalcemia caused by the Phe220Ser Gα~11~ mutation. (*A*) Effect of cinacalcet on Ca^2+^ ~i~ responses to changes in \[Ca^2+^\]~e~ of HEK‐CaSR cells transfected with WT or Ser220 Gα~11~ mutant (m). The Ca^2+^ ~i~ responses to changes in \[Ca^2+^\]~e~ are expressed as a percentage of the maximum normalized responses and shown as the mean ± SE of 6 to 12 independent transfections. The Ser220 Gα~11~ mutant led to a rightward shift in the concentration‐response curve. The addition of 30nM cinacalcet, a concentration previously shown to rectify the loss‐of‐function associated with the reported Leu135Gln Gα~11~ FHH2 mutant in vitro,[10](#jbmr3241-bib-0010){ref-type="ref"} had no effect on Ser220 responses. However, addition of 100nM cinacalcet rectified the rightward shift of the Ser220 Gα~11~ mutant, such that it was not different to WT responses. (*B*, *C*) Histograms showing (*B*) NFAT and (*C*) SRE luciferase reporter activity in response to 5mM Ca^2+^ ~e~ in HEK‐CaSR cells expressing WT or Ser220 mutant constructs, treated with vehicle or cinacalcet (CIN). Data are shown as mean ± SE of 4 independent transfections; 100nM cinacalcet was required to significantly increase NFAT and SRE reporter activity to WT levels. The responses of cells expressing WT or mutant Gα~11~ proteins were compared using the *F*‐test for *A* and 2‐way ANOVA with Tukey\'s multiple‐comparisons test for *B* and *C*. \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001. (*D*) Effect of cinacalcet on the serum ionized calcium concentrations of the FHH2 proband (individual II.1, Fig. [1](#jbmr3241-fig-0001){ref-type="fig"} *A*) with the Phe220Ser Gα~11~ mutation. Arrows indicate initiation of oral cinacalcet at 30 mg/day (CIN 30), at 60 mg/day (CIN 60), and its discontinuation. Cinacalcet treatment decreased serum concentrations of ionized calcium and PTH from 98 ng/L (pretreatment) to 58 ng/L (posttreatment) (normal range, 8 to 73 ng/L). Shaded area indicates normal range.](JBMR-33-32-g005){#jbmr3241-fig-0005}

Discussion {#jbmr3241-sec-0020}
==========

Our studies have identified a previously unreported FHH2‐causing heterozygous Gα~11~ germline loss‐of‐function mutation that represents the first loss‐of‐function Gα~11~ mutation to be located within the Gα‐subunit switch regions. The switch regions are comprised of three flexible peptide loops, which are highly conserved among all classes of Gα‐subunits, and undergo substantial conformational changes depending on the guanine nucleotide‐bound state of the Gα subunit.[30](#jbmr3241-bib-0030){ref-type="ref"} In the GTP‐bound state, these peptide loops switch their conformation to one that facilitates coupling with downstream effector proteins.[31](#jbmr3241-bib-0031){ref-type="ref"} The Phe220Ser mutation is located in the switch II region, which is predicted to bind and activate PLC,[11](#jbmr3241-bib-0011){ref-type="ref"} and our in vitro assessment of Ca^2+^ ~i~ and pERK responses in cells expressing the mutant Ser220 Gα~11~ demonstrated an impairment of signaling that is, at least in part, mediated by PLC.[26](#jbmr3241-bib-0026){ref-type="ref"}, [32](#jbmr3241-bib-0032){ref-type="ref"} Furthermore, our mutagenesis studies showed that Phe220 forms part of a group of hydrophobic residues that are required for coupling to PLC, and that Phe220 is located in a key region within this hydrophobic cleft, such that substitution of the hydrophobic Phe220 residue for a hydrophilic positively (Arg) or negatively (Glu) charged residue resulted, respectively, in a Gα~11~ gain‐of‐function or loss‐of‐function, thereby indicating that mutations of Phe220 can either retard or enhance the switch II conformational changes that occur upon G‐protein activation.

These studies have involved a comprehensive investigation of the effect of FHH2‐associated Gα~11~ mutations on PLC signaling at both the cytosolic (ie, Ca^2+^ ~i~ and pERK) and transcriptional (ie, NFAT and SRE reporter) level, and demonstrate that all readouts are affected by FHH2 mutations. The need to measure several signal outputs is increasingly important as recent studies have shown that GPCRs can couple to multiple G‐proteins to enhance their signaling capabilities and respond in diverse tissues.[33](#jbmr3241-bib-0033){ref-type="ref"}, [34](#jbmr3241-bib-0034){ref-type="ref"} Indeed, this is particularly the case in Gα~11~ mutant cells, where it has been hypothesized that other G‐proteins, in particular Gα~q~, may compensate for some of the functions of Gα~11~, giving rise to the milder phenotype observed in FHH2.[5](#jbmr3241-bib-0005){ref-type="ref"}, [6](#jbmr3241-bib-0006){ref-type="ref"} Our studies of the transcriptional events downstream of CaSR activation indicate that Ca^2+^ ~i~ signaling is more severely impaired than ERK signaling, as the Ser220 Gα~11~ mutant cells have more robust SRE signals than NFAT signals. MAPK signaling is known to occur downstream of several G‐proteins and can be used as a surrogate to assess multiple G‐protein families.[32](#jbmr3241-bib-0032){ref-type="ref"}, [35](#jbmr3241-bib-0035){ref-type="ref"} The differences observed in Ca^2+^ ~i~ signaling compared to ERK signaling in Gα~11~ Ser220 mutant cells indicates that Gα~11~ may preferentially signal via Ca^2+^ ~i~, or that other G‐proteins are able to compensate for a reduction in Gα~11~‐mediated ERK responses in FHH2 mutant cells.

The Gα~11~ protein is considered to be ubiquitously expressed,[36](#jbmr3241-bib-0036){ref-type="ref"} thus raising the possibility that germline Gα~11~ mutations may be associated with non‐calciotropic phenotypes. Indeed, in addition to constipation most of the affected family members had folliculitis or eczematous skin lesions, which may potentially represent a non‐calciotropic phenotype of FHH2. This is plausible as somatic activating Gα~11~ mutations have been reported to cause cutaneous pigmentation disorders such as dermal melanocytosis,[37](#jbmr3241-bib-0037){ref-type="ref"} and studies of atopic dermatitis, which is characterized by impaired epithelial barrier function and eczematous skin lesions, have revealed that G~q/11~‐coupled chemokine receptors facilitate the migration of inflammatory cells within the dermis.[38](#jbmr3241-bib-0038){ref-type="ref"} However, such roles of loss‐of‐function Gα~11~ mutations in cutaneous disorders remain to be elucidated, and these may be facilitated by studies of additional FHH2 patients and appropriate mouse models.

Our studies have also shown that cinacalcet‐mediated allosteric modulation of the CaSR successfully rectified the loss‐of‐function associated with the Phe220Ser Gα~11~ mutation in vitro and in vivo. However, a higher concentration of cinacalcet was required to normalize the signaling responses of cells expressing the Gα~11~ mutant Ser220, when compared to other FHH2‐causing Gα~11~ mutants.[10](#jbmr3241-bib-0010){ref-type="ref"} These in vitro findings suggest that loss‐of‐function mutations located within the Gα~11~ switch regions may alter the efficacy of calcimimetic compounds, and it is notable that the hypercalcemic proband with a Phe220Ser Gα~11~ mutation required an increase in the dose of cinacalcet from 30 to 60 mg daily to normalize the elevated serum calcium concentrations (Fig. [2](#jbmr3241-fig-0002){ref-type="fig"} *C*). Moreover, cinacalcet in the patient exerted an inhibitory effect on PTH secretion, as observed by a normalization of serum PTH concentrations. Cinacalcet may be rectifying the impaired signaling by the mutant Phe220Ser Gα~11~ by increasing signaling through the WT Gα~11~, which is present endogenously in HEK293 cells and the cells of the heterozygous patient, and/or compensatory signaling by the closely‐related Gα~q~, which activates the same signaling pathways downstream of CaSR. Importantly, hypocalcemia or adverse effects such as nausea and vomiting, which may affect \>25% of patients,[39](#jbmr3241-bib-0039){ref-type="ref"} were not observed in the patient, despite receiving a higher dose of cinacalcet.

In conclusion, we have identified a FHH2‐causing mutation, which affects the Gα~11~ switch region and disrupts PLC‐mediated signaling, and have also shown that cinacalcet can rectify these signaling disturbances and be used successfully to treat the hypercalcemia caused by this germline loss‐of‐function Gα~11~ mutation.
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